EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer

Eric X Chen, Jonathan M Loree, Emma Titmuss, Derek J Jonker, Hagen F Kennecke, Scott Berry, Felix Couture, Chaudharry E Ahmad, John R Goffin, Petr Kavan, Mohammed Harb, Bruce Colwell und 9 weitere

JAMA Network Open · 05.12.2023 · 6 (12) · e2346094

DOI: 10.1001/jamanetworkopen.2023.46094 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 05.12.2023. Verfasst von Eric X Chen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Center, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Liver Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Immune checkpoint inhibitors (ICIs) have limited activity in microsatellite-stable (MSS) or mismatch repair–proficient (pMMR) colorectal cancer. Recent findings suggest the efficacy of ICIs may be modulated by the presence of liver metastases (LM).

Objective

To investigate the association between the presence of LM and ICI activity in advanced MSS colorectal cancer. Design, Setting, and Participants In this secondary analysis of the Canadian Cancer Trials Group CO26 (CCTG CO.26) randomized clinical trial, patients with treatment-refractory colorectal cancer were randomized in a 2:1 fashion to durvalumab plus tremelimumab or best supportive care alone between August 10, 2016, and June 15, 2017. The primary end point was overall survival (OS) with 80% power and 2-sided α = .10. The median follow-up was 15.2 (0.2-22.0) months. In this post hoc analysis performed from February 11 to 14, 2022, subgroups were defined based on the presence or absence of LM and study treatments.

Intervention

Durvalumab plus tremelimumab or best supportive care. Main Outcomes and Measures Hazard ratios (HRs) and 90% CIs were calculated based on a stratified Cox proportional hazards regression model. Plasma tumor mutation burden at study entry was determined using a circulating tumor DNA assay. The primary end point of the study was OS, defined as the time from randomization to death due to any cause; secondary end points included progression-free survival (PFS) and disease control rate (DCR).

Results

Of 180 patients enrolled (median age, 65 [IQR, 36-87] years; 121 [67.2%] men; 19 [10.6%] Asian, 151 [83.9%] White, and 10 [5.6%] other race or ethnicity), LM were present in 127 (70.6%). For patients with LM, there was a higher proportion of male patients (94 of 127 [74.0%] vs 27 of 53 [50.9%]; P = .005), and the time from initial cancer diagnosis to study entry was shorter (median, 40 [range, 8-153] vs 56 [range, 14-181] months; P = .001). Plasma tumor mutation burden was significantly higher in patients with LM. Patients without LM had significantly improved PFS with durvalumab plus tremelimumab (HR, 0.54 [90% CI, 0.35-0.96]; P = .08; P = .02 for interaction). Disease control rate was 49% (90% CI, 36%-62%) in patients without LM treated with durvalumab plus tremelimumab, compared with 14% (90% CI, 6%-38%) in those with LM (odds ratio, 5.70 [90% CI, 1.46-22.25]; P = .03). On multivariable analysis, patients without LM had significantly improved OS and PFS compared with patients with LM. Conclusions and Relevance In this secondary analysis of the CCTG CO.26 study, the presence of LM was associated with worse outcomes for patients with advanced colorectal cancer. Patients without LM had improved PFS and higher DCR with durvalumab plus tremelimumab. Liver metastases may be associated with poor outcomes of ICI treatment in advanced colorectal cancer and should be considered in the design and interpretation of future clinical studies evaluating this therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsColorectal NeoplasmsLiver NeoplasmsRectal NeoplasmsAgedFemaleHumansMaleBiomarkers, TumorCanadaImmune Checkpoint InhibitorsProgression-Free SurvivalAdultMiddle AgedAged, 80 and over

Substanzen

Biomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Princess Margaret Cancer Center, Toronto, Ontario, Canada.
  • British Columbia Cancer Agency, Vancouver, Canada.
  • The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Portland Providence Cancer Center, Earle Chiles Research Institute, Portland, Oregon.
  • Department of Oncology, Queen's University, Kingston, Ontario, Canada.
  • L'Hôtel-Dieu de Québec, Laval, Quebec, Canada.

Förderung

  • NCI NIH HHS

Zitieren

APA

Chen, E. X., Loree, J. M., Titmuss, E., Jonker, D. J., Kennecke, H. F., Berry, S., Couture, F., Ahmad, C. E., Goffin, J. R., Kavan, P., Harb, M., Colwell, B., Samimi, S., Samson, B., Abbas, T., Aucoin, N., Aubin, F., Koski, S., Wei, A. C., …, & O'Callaghan, C. J. (2023). Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer. JAMA Network Open, 6(12), e2346094. https://doi.org/10.1001/jamanetworkopen.2023.46094

Vancouver

Chen EX, Loree JM, Titmuss E, Jonker DJ, Kennecke HF, Berry S, et al. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer. JAMA Network Open. 2023;6(12):e2346094. doi:10.1001/jamanetworkopen.2023.46094

BibTeX
@article{Chen2023,
  author = {Chen, Eric X and Loree, Jonathan M and Titmuss, Emma and Jonker, Derek J and Kennecke, Hagen F and Berry, Scott and Couture, Felix and Ahmad, Chaudharry E and Goffin, John R and Kavan, Petr and Harb, Mohammed and Colwell, Bruce and Samimi, Setareh and Samson, Benoit and Abbas, Tahir and Aucoin, Nathalie and Aubin, Francine and Koski, Sheryl and Wei, Alice C and Tu, Dongsheng and O'Callaghan, Chris J},
  title = {Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {12},
  pages = {e2346094},
  doi = {10.1001/jamanetworkopen.2023.46094}
}
Kostenlos starten →